MetLife Investment Management’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-34,106
| Closed | -$311K | – | 2906 |
|
|
2025
Q2 | $311K | Buy |
34,106
+3,127
| +10% | +$23K | ﹤0.01% | 1937 |
|
|
2025
Q1 | $246K | Buy |
30,979
+5,343
| +21% | +$39.1K | ﹤0.01% | 2090 |
|
|
2024
Q4 | $139K | Sell |
25,636
-5,076
| -17% | -$31K | ﹤0.01% | 2474 |
|
|
2024
Q3 | $222K | Hold |
30,712
| – | – | ﹤0.01% | 2234 |
|
|
2024
Q2 | $334K | Buy |
30,712
+3,029
| +11% | +$38.8K | ﹤0.01% | 1945 |
|
|
2024
Q1 | $519K | Hold |
27,683
| – | – | ﹤0.01% | 1653 |
|
|
2023
Q4 | $600K | Hold |
27,683
| – | – | ﹤0.01% | 1582 |
|
|
2023
Q3 | $570K | Hold |
27,683
| – | – | ﹤0.01% | 1549 |
|
|
2023
Q2 | $1.3M | Buy |
27,683
+558
| +2% | +$27.8K | 0.01% | 1130 |
|
|
2023
Q1 | $1.14M | Hold |
27,125
| – | – | 0.01% | 1163 |
|
|
2022
Q4 | $1.03M | Hold |
27,125
| – | – | 0.01% | 1204 |
|
|
2022
Q3 | $1.06M | Hold |
27,125
| – | – | 0.01% | 1158 |
|
|
2022
Q2 | $876K | Buy |
27,125
+26,098
| +2,541% | +$875K | 0.01% | 1279 |
|
|
2022
Q1 | $34K | Buy |
+1,027
| New | +$38.6K | ﹤0.01% | 2689 |
|
|
2019
Q2 | – | Sell |
-67
| Closed | -$10.7K | – | 2566 |
|
|
2019
Q1 | $10.7K | Buy |
67
+5
| +8% | +$724 | ﹤0.01% | 2391 |
|
|
2018
Q4 | $5.94K | Sell |
62
-1
| -2% | -$114 | ﹤0.01% | 2445 |
|
|
2018
Q3 | $8.9K | Buy |
+63
| New | +$9.72K | ﹤0.01% | 2454 |
|
|
2018
Q2 | – | Sell |
-18,484
| Closed | -$2.98M | – | 2216 |
|
|
2018
Q1 | $2.98M | Buy |
18,484
+1,458
| +9% | +$248K | 0.04% | 617 |
|
|
2017
Q4 | $2.8M | Buy |
+17,026
| New | +$1.65M | 0.03% | 673 |
|
Other funds holding SAGE
IA
HNB
MetLife Investment Management's SAGE Position: Q3 2025 in Review
MetLife Investment Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 34,106 shares — an estimated $311K sold.
MetLife Investment Management first reported a position in SAGE in Q4 2017 and held it in 19 quarters. The position peaked at $2.98M in Q1 2018. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- MetLife Investment Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- MetLife Investment Management sold 34,106 Sage Therapeutics shares in Q3 2025, an estimated $311K.
- MetLife Investment Management first reported a position in Sage Therapeutics in Q4 2017 and held it in 19 quarters.
- MetLife Investment Management's Sage Therapeutics position peaked at $2.98M in Q1 2018.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on MetLife Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.